Results 81 to 90 of about 173,877 (309)

Melatonin and sciatic nerve injury repair: a current perspective

Journal of Neurorestoratology, 2018
Berrin Zuhal Altunkaynak,1 Burcu Delibaş,2 Gamze Altun,2 Ömür Gülsüm Deniz2 1Department of Histology and Embryology, Medical Faculty, Okan University, Istanbul; Turkey; 2Department of Histology and Embryology, Medical Faculty, Ondokuz
Altunkaynak BZ, Delibaş B, Altun G, Deniz ÖG   +3 more
doaj  

Longitudinal Assessment of Biomarkers in ALS: Discriminative Biomarkers for Disease Progression and Survival

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To assess the association and discriminative performance of serum biomarkers with clinical disease progression and survival in patients with amyotrophic lateral sclerosis (ALS). Methods This retrospective study, conducted at Houston Methodist Hospital, Houston, TX, used longitudinal serum samples collected between January 2018 and ...
David R. Beers, Yueh‐Yun Lin, Jason R. Thonhoff, Aaron D. Thome, Alireza Faridar, Weihua Zhao, Shixiang Wen, Stanley H. Appel   +7 more
wiley   +1 more source

The value of psychosocial factors in predicting postoperative somatoform disorder and surgical outcome in patients operated for Degenerative Disc Disease (DDD) - a preliminary study

Brain and Spine, 2022
R. Jabbar, A. Pawelczyk, R. Jekimov, T. Pawelczyk, M. Radek   +4 more
doaj   +1 more source

Prognostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in ALD‐Related Myelopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background X‐linked adrenoleukodystrophy (X‐ALD) is a neurometabolic disorder caused by pathogenic variants in ABCD1, leading to slowly progressive spinal cord disease in nearly all affected men. Sensitive biomarkers to quantify disease severity and predict progression are needed for clinical care and trial design.
Eda G. Kabak, Marije M. C. Voermans, Hans Heijst, Charlotte E. Teunissen, Marc Engelen   +4 more
wiley   +1 more source

Segmentation of Peripheral Nerves From Magnetic Resonance Neurography: A Fully-Automatic, Deep Learning-Based Approach [PDF]

, 2018
Diagnosis of peripheral neuropathies relies on neurological examinations, electrodiagnostic studies, and since recently magnetic resonance neurography (MRN).
Scheidegger, Olivier, Olivier Scheidegger, Carolin Steindel, Mirjam Arn, Balsiger, Fabian, Steindel, Carolin, Benedikt Wagner, Wagner, Benedikt, Waldo Valenzuela, Fabian Balsiger, Grunder, Lorenz Nicolas, Valenzuela, Waldo Enrique, Mauricio Reyes, El-Koussy, Marwan, Reyes, Mauricio, Lorenz Grunder, Arn, Mirjam, Marwan El-Koussy   +17 more
core   +1 more source

Understanding Further the Phenotypic Spectrum of Central Nervous System Inflammatory Demyelinating Disorders Using Unsupervised Clustering

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Central nervous system (CNS) inflammatory demyelinating syndromes, including multiple sclerosis (MS), aquaporin‐4 antibody–positive neuromyelitis optica spectrum disorder (AQP4 + NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody–associated disease (MOGAD), occasionally overlap.
Bade Gulec, Elif Everest, Melih Tutuncu, Ugur Bilge, Sabahattin Saip, Ugur Uygunoglu, Aksel Siva   +6 more
wiley   +1 more source

Peripheral Nerve [PDF]

Operative Neurosurgery, 2019
Robert J, Spinner, Amgad S, Hanna, Andrés A, Maldonado, Thomas J, Wilson   +3 more
openaire   +2 more sources

Ultrasonography of peripheral nerves.

, 1996
During sonographic examination of the extremities using high frequency "small-parts" equipment, peripheral nerves may be identified in virtually all patients.
MARTINOLI, CARLO, M. Bertolotto, DERCHI, LORENZO, S. Bianchi, G. Serafini, N. Gandolfo   +5 more
core  

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Dimethyl Fumarate, But Not Rituximab, Reduces Serum GFAP Levels and PIRMA in Relapsing–Remitting MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Serum neurofilament light chain (sNfL) and glial fibrillary acidic protein (sGFAP) levels are believed to reflect mainly acute and chronic disease processes in multiple sclerosis (MS), respectively. In this study, we investigated whether dimethyl fumarate (DMF) and rituximab (RTX) differentially affect these biomarkers.
F. Shawket, J. Lycke, J. Salzer, F. Piehl, K. Fink, N. Lange, J. Mellergård, C. Malmeström, P. Sundström, I. Erngren, A. al‐Grety, E. Freyhult, K. Kultima, J. Burman, A. Svenningsson   +14 more
wiley   +1 more source